Skip to Main Content

Advertisement intended for health care professionals

Close

ASH Clinical News
ASH News Daily
ASH-SAP
Blood Journals
Hematology
The Hematologist
International
ASH
- ASH Home
- Research
- Education
- Advocacy
- Meetings
- Publications
- ASH Store

header search

search input Search input auto suggest

filter your search

Search

Menu

Issues
- Current Issue
- All Issues
First edition
Abstracts
Collections
Author Center
About

Skip Nav Destination

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS| March 20, 2025

Zanubrutinib, venetoclax, and obinutuzumab in R/R CLL

CME

Blood (2025) 145 (12): 1334.

https://doi.org/10.1182/blood.2025028638

Connected Content

A related article has been published: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Split-Screen
Share
- Facebook
- Twitter
- LinkedIn
- Email
Tools
- Request Permissions
- Cite
Search Site
Open the PDF for in another window

Citation

Zanubrutinib, venetoclax, and obinutuzumab in R/R CLL. Blood 2025; 145 (12): 1334. doi: https://doi.org/10.1182/blood.2025028638

Download citation file:

Ris (Zotero)
Reference Manager
EasyBib
Bookends
Mendeley
Papers
EndNote
RefWorks
BibTex

toolbar search

toolbar search

search input Search input auto suggest

filter your search

Search

Subjects:

CME article, Free Research Articles

This content is only available as a PDF.

© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

2025

Article PDF first page preview

Article PDF first page preview

Article PDF first page preview

Sign in via your Institution

Submit a comment

Name Please enter your name.

Affiliations Please enter your affiliations

Comment title Please supply a title for your comment.

Comment This field is required

I agree to the terms and conditions. You must accept the terms and conditions.

Read the terms and conditions

You have entered an invalid code.

Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.

Comment not saved. Please try again.

This feature is available to Subscribers Only

Sign In or Create an Account

My Account

Volume 145, Issue 12

March 20 2025

Previous Article

Advertisement intended for health care professionals

Sign in via your Institution

View Metrics

×

Cited By

Google Scholar

Email alerts

Article Activity Alert

First Edition Alert

Latest Issue Alert

Advertisement intended for health care professionals

Advertisement intended for health care professionals

About Blood
Abstracts
Advertising in Blood

Alerts
All Issues
Author Guide

Blood Classifieds
Collections
Contact Us

Current Issue
First edition
Newsroom

Permissions
Public Access
Subscriptions

Submit to Blood
Terms and Conditions

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Blood Global Hematology
Blood Immunology & Cellular Therapy
Blood Neoplasia
Blood Red Cells & Iron
Blood Vessels, Thrombosis & Hemostasis
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
Research
Education
Advocacy
Meetings
Publications
ASH Store

Copyright 2024 by American Society of Hematology

Cookie Settings
Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account

Advertisement intended for health care professionals